Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

375
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
375
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation of a Structured, Protocol-Based Hypertension Management Strategy in Romanian Primary Care: A Single-Arm Exploratory Study.

Cureus·2026
Same author

Thyroid hormone therapy in a population cohort over two decades indicates persistent overtreatment.

European thyroid journal·2026
Same author

Associations Between Physical Fitness and Health-Related Quality of Life in Children with Obesity.

Diagnostics (Basel, Switzerland)·2026
Same author

Sotatercept in Pulmonary Arterial Hypertension: Molecular Mechanisms, Clinical Evidence, and Emerging Role in Reverse Remodelling.

International journal of molecular sciences·2026
Same author

Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on "Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Diagnostics</i> 2025, <i>15</i>, 2126".

Diagnostics (Basel, Switzerland)·2026
Same author

Inflammation-Based Hematologic Indices as Prognostic Markers in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Hypothesis-Generating Registry Study.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Dec 22, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K

PD-1 Blockade in Anaplastic Thyroid Carcinoma.

Jaume Capdevila1, Lori J Wirth2, Thomas Ernst3

  • 1Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 5, 2020
PubMed
Summary

Spartalizumab, a PD-1 inhibitor, showed a 19% response rate in advanced anaplastic thyroid carcinoma. Responses were higher in patients with PD-L1 expression, indicating potential for this immunotherapy.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.2K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.5K

Related Experiment Videos

Last Updated: Dec 22, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.2K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thyroid Cancer Research

Background:

  • Anaplastic thyroid carcinoma is a fatal cancer with limited treatment options.
  • Targeting the programmed death-1 (PD-1) receptor offers a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy and safety of spartalizumab in patients with advanced or metastatic anaplastic thyroid carcinoma.
  • To assess response rates in relation to PD-L1 expression and BRAF mutation status.

Main Methods:

  • A phase II clinical trial enrolled 42 patients with advanced/metastatic anaplastic thyroid carcinoma.
  • Patients received intravenous spartalizumab (400 mg every 4 weeks).
  • Tumor response was assessed using RECIST v1.1 criteria, with PD-L1 expression analyzed from baseline biopsies.

Main Results:

  • The overall response rate was 19% (3 complete responses, 5 partial responses).
  • Response rates were significantly higher in PD-L1-positive patients (29%) compared to PD-L1-negative patients (0%).
  • Durable responses and improved survival were observed in the PD-L1-positive group, with a 1-year survival of 52.1%.

Conclusions:

  • Spartalizumab demonstrates clinical activity in anaplastic thyroid carcinoma, representing a potential new treatment avenue.
  • PD-L1 expression is a predictive biomarker for response to PD-1 blockade in this patient population.
  • This study is the first to report responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.